Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand
NCT ID: NCT02293564
Last Updated: 2015-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
312 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01683396
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01882491
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
NCT02159053
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
NCT02165345
Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis
NCT00597623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gevokizumab
gevokizumab
Solution for subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gevokizumab
Solution for subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Joint tenderness and/or redness
* At least one erosion by X-ray (as determined by the central reader)
* Contraceptive measures adequate to prevent pregnancy during the study
Exclusion Criteria
* History of gout, pseudogout, or hemochromatosis
* History of allergic or anaphylactic reactions to monoclonal antibodies
* History of recurrent or chronic systemic infections
* Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XOMA (US) LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Roseville, California, United States
Sacramento, California, United States
Santa Monica, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Miami, Florida, United States
Pinellas Park, Florida, United States
Tampa, Florida, United States
Vero Beach, Florida, United States
West Palm Beach, Florida, United States
Indianapolis, Indiana, United States
Wichita, Kansas, United States
Hagerstown, Maryland, United States
Wheaton, Maryland, United States
Reno, Nevada, United States
Albuerque, New Mexico, United States
Raleigh, North Carolina, United States
Portland, Oregon, United States
Duncansville, Pennsylvania, United States
Austin, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Waco, Texas, United States
Charlottesville, Virginia, United States
Norfolk, Virginia, United States
Franklin, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X052161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.